RCEL Stock Forecast & Price Target

AVITA Medical is supported by a differentiated RECELL platform that meaningfully improves burn care by enabling Spray-On Skin from a small sample in about 30 minutes, reducing donor skin requirements, and showing clinical efficacy and cost-effectiveness versus standard skin grafting. The investment case is strengthened by evidence of accelerating commercial execution, including record revenue of ~$21.7M (+18% Y/Y), FY26 guidance raised to $86M-$89M, all seven MACs publishing payment rates, US RECELL volume up ~11% sequentially, and an expectation of cash flow break-even in 4Q26. Its upside is further underpinned by a broadening product and reimbursement backdrop, with RECELL already used in most of the 140 US burn centers, a 10-year BARDA agreement valued at up to ~$25.5M, and proposed CY27 coding changes that could simplify billing and support broader adoption.

AVITA Medical is a largely single-product company whose reliance on RECELL creates meaningful concentration risk, leaving the business vulnerable if utilization, reimbursement, or competitive adoption slows despite its approval across adult and paediatric burn care and soft-tissue reconstruction. Although RECELL usage is improving, with total US volume up about 11% sequentially in 2Q26 to over 2,600 units and RECELL GO mini contributing incremental demand, the company still appears financially constrained, exiting 2Q26 with only about $11.1M in cash and cash equivalents against roughly $3.2M in cash burn, underscoring limited balance-sheet flexibility. The 10-year BARDA agreement valued at up to $25.5M is strategically helpful but economically modest, with only about $3.97M expected over the full term, and because AVITA is not actively marketing in Australia, Canada, and China, the growth narrative remains heavily dependent on the US while international traction is still relatively narrow.